BSVN vs GSK · P/E 9.2, rev $64.7M vs P/E 13, $103.31B cap
Bank7 Corp (BSVN) versus GlaxoSmithKline PLC ADR (GSK) — a side-by-side from cached financials, not a winner call.
Bank7 Corp (BSVN) is a banks - regional company listed on US.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Latest reported BSVN revenue for 2026-06-30 was $64.7M. Net income was $20.4M. Revenue was up 91.5% from 2026-03-31 to 2026-06-30. BSVN currently screens at market cap $420.2M and trailing P/E 9.2.
GSK does not have a complete income-statement cache yet.
BSVN currently screens at market cap $420.2M and trailing P/E 9.2. GSK currently screens at market cap $103.31B and trailing P/E 13.5.
Not investment advice. Open the BSVN and GSK stock pages for the full models.
Not investment advice.